Avantor Performance Materials

Flexion Therapeutics Inc, based in Burlington, MA, is at the forefront of transforming pain management through the development of precise, targeted non-opioid therapies aimed at improving the lives of patients suffering from chronic, postsurgical, and musculoskeletal pain. The company is dedicated to addressing unmet medical needs by researching advanced therapies, including innovative gene therapy solutions. Committed to meaningful change, Flexion Therapeutics emphasizes education and advocacy to enhance patient care and expand access to safe and effective non-opioid treatments. Their team is united by a passion for excellence and a dedication to making a real impact in the field of pain management. Generated from the website

Cequent Pharmaceuticals, a privately held biopharmaceutical company based in Cambridge, Massachusetts, is at the forefront of developing novel therapeutics aimed at preventing and treating a variety of human diseases, including inflammatory diseases and cancer. Established in 2006, the company leverages its proprietary TransKingdom RNA interference (tkRNAi) technology to target specific disease-causing genes safely and effectively using non-pathogenic bacteria as delivery vehicles. The tkRNAi platform enables the development of drug candidates that can silence one or more cellular genes simultaneously, offering a powerful alternative to traditional small molecules and monoclonal antibodies. With its foundation rooted in groundbreaking scientific research from the Institut Pasteur in Paris and Beth Israel Deaconess Medical Center at Harvard Medical School, Cequent is poised to make significant advancements in the biopharmaceutical landscape. Generated from the website

scPharmaceuticals Inc., based in Burlington, MA, is focused on advancing innovations in cardiovascular and renal care through patient-centric approaches that aim to enhance health outcomes and improve quality of life. The company's commitment to integrated treatments addresses unmet patient needs, positioning it as a leader in the cardiorenal space. With expertise in drug-device combinations and product commercialization, scPharmaceuticals is dedicated to delivering value-based treatments for heart failure and chronic kidney disease. The firm's recent developments, including the launch of FUROSCIX for chronic kidney disease, reflect its ongoing mission to redefine healthcare standards and empower patients. Generated from the website